HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia—rationale, study design and protocol

Abstract Background Diabetic macular ischaemia (DMI) is a complication of diabetic retinopathy that leads to irreversible vision loss. DMI is characterised by reduced retinal vessel density and enlargement of the foveal avascular zone (FAZ). Despite its clinical burden, there is no formal consensus...

Full description

Bibliographic Details
Published in:Trials
Main Authors: Victor Chong, Quan Dong Nguyen, Yasir Sepah, Andrea Giani, Elizabeth Pearce
Format: Article
Language:English
Published: BMC 2022-08-01
Subjects:
Diabetic retinopathy
Diabetic macular ischaemia
Clinical trial
HORNBILL
OCTA
OCT
Online Access:https://doi.org/10.1186/s13063-022-06527-y

Internet

https://doi.org/10.1186/s13063-022-06527-y

Similar Items